Sergei Varlamov

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Robert J. Motzer, Naomi B. Haas, Frede Donskov et al. · Journal of Clinical Oncology · 2017 · 382 citations

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · The Lancet Oncology · 2022 · 162 citations · Full text

Urology, Oncology, Metastatic Urothelial Carcinoma +7

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and <i>FGFR</i> alterations (FGFRalt).

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · Journal of Clinical Oncology · 2018 · 73 citations

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Robert J. Motzer, Paul Russo, Naomi B. Haas et al. · European Urology · 2021 · 62 citations · Full text

Urology, Surgical Oncology, Genitourinary Cancer +6

Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

Ilya Tsimafeyeu, Tatiana Zolotareva, Sergei Varlamov et al. · Clinical Genitourinary Cancer · 2017 · 34 citations

Surgical Oncology, Urology, Russian Federation +7